Literature DB >> 6292472

Molecular cloning of a highly leukemogenic, ecotropic retrovirus from an AKR mouse.

J Lenz, R Crowther, S Klimenko, W Haseltine.   

Abstract

SL3-3 is a leukemogenic, ecotropic retrovirus produced by a T-cell line derived from a spontaneous lymphoma of an AKR mouse. We have isolated a molecular clone of its DNA provirus from infected NIH 3T3 fibroblasts. Cloned proviral DNA produced infectious virus upon transfection onto NIH 3T3 cells. Virus derived by transfection induced lymphomas at high frequency in AKR/J, C3H(f)/Bi, CBA/J, and NFS/N mice. Heteroduplex and RNase T1 fingerprinting analyses showed that the genomes of SL3-3 and the non-leukemogenic virus, Akv, contain no major substitutions relative to one another and differ by only a few base changes. These results unambiguously show that SL3-3 is a highly leukemogenic virus and that major rearrangements of the genome relative to Akv are not required for virulence.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6292472      PMCID: PMC256205     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  38 in total

1.  Biochemical evidence that MCF murine leukemia viruses are envelope (env) gene recombinants.

Authors:  J H Elder; J W Gautsch; F C Jensen; R A Lerner; J W Hartley; W P Rowe
Journal:  Proc Natl Acad Sci U S A       Date:  1977-10       Impact factor: 11.205

2.  Characterization and mapping of RNase T1-resistant oligonucleotides derived from the genomes of Akv and MCF murine leukemia viruses.

Authors:  J Rommelaere; D V Faller; N Hopkins
Journal:  Proc Natl Acad Sci U S A       Date:  1978-01       Impact factor: 11.205

3.  Oncogenicity of AKR endogenous leukemia viruses.

Authors:  R C Nowinski; E F Hays
Journal:  J Virol       Date:  1978-07       Impact factor: 5.103

4.  Screening lambdagt recombinant clones by hybridization to single plaques in situ.

Authors:  W D Benton; R W Davis
Journal:  Science       Date:  1977-04-08       Impact factor: 47.728

5.  A comparison of two cloned mouse beta-globin genes and their surrounding and intervening sequences.

Authors:  D C Tiemeier; S M Tilghman; F I Polsky; J G Seidman; A Leder; M H Edgell; P Leder
Journal:  Cell       Date:  1978-06       Impact factor: 41.582

6.  Charon phages: safer derivatives of bacteriophage lambda for DNA cloning.

Authors:  F R Blattner; B G Williams; A E Blechl; K Denniston-Thompson; H E Faber; L Furlong; D J Grunwald; D O Kiefer; D D Moore; J W Schumm; E L Sheldon; O Smithies
Journal:  Science       Date:  1977-04-08       Impact factor: 47.728

7.  A new class of murine leukemia virus associated with development of spontaneous lymphomas.

Authors:  J W Hartley; N K Wolford; L J Old; W P Rowe
Journal:  Proc Natl Acad Sci U S A       Date:  1977-02       Impact factor: 11.205

8.  A discrepancy in XC and oncogenicity assays for murine leukemia virus in AKR mice.

Authors:  E F Hays; D L Vredevoe
Journal:  Cancer Res       Date:  1977-03       Impact factor: 12.701

9.  Leukemogenic activity of murine type C viruses after long-term passage in vitro.

Authors:  D L Buchhagen; T Pincus; O Stutman; E Fleissner
Journal:  Int J Cancer       Date:  1976-12-15       Impact factor: 7.396

10.  Assay for type C virus in mouse sera based on particulate reverse transcriptase activity.

Authors:  P Roy-Burman; M Dougherty; B K Pal; H P Charman; V Klement; M B Gardner
Journal:  J Virol       Date:  1976-09       Impact factor: 5.103

View more
  25 in total

1.  Disruption of hematopoiesis and thymopoiesis in the early premalignant stages of infection with SL3-3 murine leukemia virus.

Authors:  Karen Rulli; Jack Lenz; Laura S Levy
Journal:  J Virol       Date:  2002-03       Impact factor: 5.103

2.  Increased induction of osteopetrosis, but unaltered lymphomagenicity, by murine leukemia virus SL3-3 after mutation of a nuclear factor 1 site in the enhancer.

Authors:  S Ethelberg; B D Tzschaschel; A Luz; S J Diaz-Cano; F S Pedersen; J Schmidt
Journal:  J Virol       Date:  1999-12       Impact factor: 5.103

3.  Increased lymphomagenicity and restored disease specificity of AML1 site (core) mutant SL3-3 murine leukemia virus by a second-site enhancer variant evolved in vivo.

Authors:  S Ethelberg; J Lovmand; J Schmidt; A Luz; F S Pedersen
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

4.  Control of pathogenicity and disease specificity of a T-lymphomagenic gammaretrovirus by E-box motifs but not by an overlapping glucocorticoid response element.

Authors:  Ditte Ejegod; Karina Dalsgaard Sørensen; Ilona Mossbrugger; Leticia Quintanilla-Martinez; Jörg Schmidt; Finn Skou Pedersen
Journal:  J Virol       Date:  2008-10-22       Impact factor: 5.103

5.  An MuLV transmission vector system designed to permit recovery in E. coli of proviral and cellular flanking sequences.

Authors:  P Jørgensen; T Mikkelsen; F S Pedersen; N O Kjeldgaard
Journal:  Virus Genes       Date:  1988-03       Impact factor: 2.332

6.  Differential protein binding in lymphocytes to a sequence in the enhancer of the mouse retrovirus SL3-3.

Authors:  A Thornell; B Hallberg; T Grundström
Journal:  Mol Cell Biol       Date:  1988-04       Impact factor: 4.272

7.  Replication and pathogenicity of primer binding site mutants of SL3-3 murine leukemia viruses.

Authors:  A H Lund; J Schmidt; A Luz; A B Sørensen; M Duch; F S Pedersen
Journal:  J Virol       Date:  1999-07       Impact factor: 5.103

8.  Sequence tags of provirus integration sites in DNAs of tumors induced by the murine retrovirus SL3-3.

Authors:  A B Sørensen; M Duch; H W Amtoft; P Jørgensen; F S Pedersen
Journal:  J Virol       Date:  1996-06       Impact factor: 5.103

9.  Coupling of receptor interference and a host-dependent post-binding entry deficiency in a gammaretroviral envelope protein.

Authors:  Shervin Bahrami; Ditte Ejegod; Karina Dalsgaard Sørensen; Finn Skou Pedersen
Journal:  Retrovirology       Date:  2010-02-05       Impact factor: 4.602

10.  Suppression of retroviral propagation and disease by suramin in murine systems.

Authors:  R M Ruprecht; L D Rossoni; W A Haseltine; S Broder
Journal:  Proc Natl Acad Sci U S A       Date:  1985-11       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.